POSTPRANDIAL LIPOPROTEIN METABOLISM IN OBESE PATIENTS WITH MODERATE HYPERTRIGLYCERIDEMIA - EFFECTS OF GEMFIBROZIL

被引:7
作者
DITSCHUNEIT, HH
FLECHTNERMORS, M
HAGEL, E
DITSCHUNEIT, H
机构
[1] UNIV ULM, DEPT INTERNAL MED, ROBERT KOCH STR 8, W-7900 ULM, GERMANY
[2] UNIV ULM, DEPT INTERNAL MED GASTROENTEROL & NUTR 2, W-7900 ULM, GERMANY
关键词
GEMFIBROZIL; OBESITY; HYPERTRIGLYCERIDEMIA; POSTPRANDIAL LIPEMIA; TRIGLYCERIDES; LIPOPROTEINS;
D O I
10.1177/030006059202000301
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
After an oral fat load of 1 g/kg body weight in lo obese females with hyperlipoproteinaemia type IV, serum triglycerides concentrations were maximal at 4 h with a slight decline at 6 h, whereas serum cholesterol concentrations rose slightly at 4 h and 6 h. After 6 h, concentrations of triglycerides and cholesterol were significantly increased in chylomicrons and very low-density lipoprotein [VLDL], whereas cholesterol concentrations were decreased in high-density lipoprotein 2 [HDL2] plus HDL3. After oral treatment with 450 mg gemfibrozil twice daily for 28 days, triglyceride concentrations were reduced in serum, chylomicrons, VLDL and low-density lipoprotein, and total cholesterol concentrations were reduced in serum, chylomicrons and VLDL, and increased in HDL2 plus HDL3. At 6 h after a fat load following 28 days' gemfibrozil treatment, triglyceride and cholesterol concentrations were reduced in serum, chylomicrons and VLDL when compared with pretreatment results. It is concluded that gemfibrozil is effective in lowering triglycerides and cholesterol, particularly in triglyceride-rich particles, and raising the cholesterol content of HDL2 plus HDL3. After an oral fat load gemfibrozil inhibits the increase in serum cholesterol and partly prevents postprandial hypertriglyceridaemia.
引用
收藏
页码:197 / 210
页数:14
相关论文
共 61 条
[1]  
[Anonymous], 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138
[2]   PLASMA TRIGLYCERIDE AS A RISK FACTOR FOR CORONARY HEART-DISEASE - THE EPIDEMIOLOGIC EVIDENCE AND BEYOND [J].
AUSTIN, MA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1989, 129 (02) :249-259
[3]  
Bierman EL, 1987, HARRISONS PRINCIPLES, P1014
[4]  
BODE G, 1981, ADV PHYSL SCI, V35, P305
[5]   HYPERTRIGLYCERIDEMIA ASSOCIATED WITH DEFICIENCY OF APOLIPOPROTEIN-C-II [J].
BRECKENRIDGE, WC ;
LITTLE, JA ;
STEINER, G ;
CHOW, A ;
POAPST, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (23) :1265-1273
[6]   SERUM TRIGLYCERIDES IN HEALTH AND IN ISCHEMIC HEART DISEASE [J].
BROWN, DF ;
KINCH, SH ;
DOYLE, JT .
NEW ENGLAND JOURNAL OF MEDICINE, 1965, 273 (18) :947-&
[7]   IS THE LEVEL OF SERUM TRIGLYCERIDE A SIGNIFICANT PREDICTOR OF CORONARY DEATH IN NORMOCHOLESTEROLEMIC SUBJECTS - THE PARIS PROSPECTIVE-STUDY [J].
CAMBIEN, F ;
JACQUESON, A ;
RICHARD, JL ;
WARNET, JM ;
DUCIMETIERE, P ;
CLAUDE, JR .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1986, 124 (04) :624-632
[8]  
CARLSON LA, 1979, ACTA MED SCAND, V206, P351
[9]   THE TRIGLYCERIDE ISSUE - A VIEW FROM FRAMINGHAM [J].
CASTELLI, WP .
AMERICAN HEART JOURNAL, 1986, 112 (02) :432-437
[10]  
CATTIN L, 1989, Advances in Therapy, V6, P16